At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22 enrolled
Drug / intervention
Mirceradrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Interventional Study to Document the Efficacy in Routine Clinical Practice of Mircera in Pakistan (NORM)
In Brief
An observational study evaluating Mircera for Anemia. Completed, enrolled 22 participants across 6 sites.
Detailed Summary
This observational, prospective, multi-centre, single-arm study will evaluate the efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease previously on treatment with short-acting epoetin alpha. Data will be collected for 6 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesPakistan
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedAug 2011
Primary CompletionMar 2012
TodayJul 2026
First PostedAug 16, 2011
Enrollment StartMay 31, 2010
Primary CompletionMar 31, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.9 years ago
Interventions
Mirceradrug
Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.